2021-2023 US GLP-1RAs prescriptions surged for Type 2 diabetes and obesity treatment, per Cedars-Sinai study in Annals of Internal Medicine.
A study by Cedars-Sinai and other institutions found a surge in prescriptions for GLP-1 receptor agonists (GLP-1RAs), medications used to treat Type 2 diabetes and obesity. The research, published in Annals of Internal Medicine, examined the use of GLP-1RAs in the US from 2011 to 2023, identifying trends in the prescription patterns for treating Type 2 diabetes versus obesity. Since 2021, the US FDA has approved GLP-1RAs for chronic weight management in adults with obesity or those with overweight and obesity-related conditions.
July 22, 2024
8 Articles